#1 Clinical Trials Search in Europe

Study on the Effectiveness and Safety of Reparixin for Adults with Acute Respiratory Distress Syndrome

2 1

What is this study about?

This clinical trial is focused on studying a condition known as Acute Respiratory Distress Syndrome (ARDS), which is a severe lung condition that causes difficulty in breathing. The study is testing a medication called Reparixin, which is taken as a tablet. Reparixin is being investigated to see if it can help improve lung function and reduce inflammation in patients with ARDS. The trial will also compare the effects of Reparixin with a placebo, which looks like the medication but does not contain any active ingredients.

The purpose of the study is to evaluate how effective and safe Reparixin is when used alongside the standard care for ARDS. Participants in the study will receive either Reparixin or a placebo, and their progress will be monitored over a period of time. The study aims to see if Reparixin can help patients recover more quickly and reduce their need for mechanical ventilation, which is a machine that helps with breathing.

Throughout the study, researchers will observe changes in the patients’ lung function and overall health. They will also look at specific markers in the blood that are linked to inflammation. The study will last for several weeks, and the results will help determine if Reparixin can be a beneficial treatment for people with ARDS.

1 Joining the study

Participation begins after signing an informed consent form. This confirms understanding and agreement to participate in the study.

Eligibility is confirmed based on criteria such as age, medical condition, and current treatment status.

2 Initial assessment

An initial assessment is conducted to establish baseline health status. This includes measuring oxygen levels and other health indicators.

3 Medication administration

Participants receive either reparixin or a placebo. Both are administered in tablet form for oral use.

The dosage and frequency of administration are determined by the study protocol and are monitored by the medical team.

4 Monitoring and follow-up

Health status is monitored regularly to assess the effects of the medication. This includes checking oxygen levels and other vital signs.

Regular assessments are conducted on days 2, 3, 4, 7, 14, and 28 to evaluate progress and any changes in health status.

5 Completion of treatment phase

The primary treatment phase concludes on day 28. The number of days without the need for a ventilator is recorded.

Additional health assessments are conducted to evaluate recovery and any remaining symptoms.

6 Final assessment and study conclusion

A final assessment is conducted to evaluate overall health and recovery status.

The study concludes with a review of all collected data to determine the efficacy and safety of the treatment.

Who Can Join the Study?

  • The patient must provide a signed informed consent, following local guidelines and rules.
  • The patient must be an adult, meaning they are over 18 years old.
  • The patient must be on a breathing machine (mechanically ventilated) with a specific measurement called the PaO2/FIO2 ratio being 200 or less, and a PEEP (a setting on the breathing machine) of 5 cm H2O or more.
  • The patient’s breathing problems should not be completely due to heart problems or too much fluid in the body. If heart failure is part of the problem, it should be treated quickly before joining the study.
  • The patient must have certain findings on a chest x-ray or CT scan that show signs of fluid in the lungs, known as pulmonary edema or ground glass opacities.
  • The patient must be enrolled in the study within 48 hours of meeting the above criteria. If transferred from another hospital, an extra 12 hours is allowed.
  • Females who can have children and are sexually active must agree not to become pregnant for 30 days after the last dose of the study drug. They must use reliable birth control methods, such as hormonal birth control, a sterile partner, or abstinence. If the patient cannot consent due to illness, a legal representative must assure this, and the patient must confirm when able. Females who cannot have children or have been in menopause for at least a year can join. A negative pregnancy test is required before starting the study drug.

Who Cannot Join the Study?

  • Patients who are pregnant or breastfeeding cannot participate.
  • Individuals with a history of severe allergic reactions to similar medications are excluded.
  • Patients with other serious health conditions that might interfere with the study are not eligible.
  • People who have participated in another clinical trial recently are not allowed to join.
  • Individuals with a history of drug or alcohol abuse may be excluded.
  • Patients who are unable to follow the study procedures or instructions cannot participate.
  • Anyone with a mental health condition that affects their ability to consent or comply with the study is excluded.
  • Patients with certain infections that could affect the study results are not eligible.
  • Individuals who have received certain treatments that might interfere with the study are excluded.
  • Patients with a history of certain lung diseases that are not related to the study condition cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Universitaetsmedizin Goettingen Goettingen Germany
Universitaet Leipzig Leipzig Germany

Other Sites

Site Name City Country Status
Universitaetsklinikum Schleswig-Holstein AöR Kiel Germany
BG Klinikum Bergmannstrost Halle gGmbH Halle (Saale) Germany
Ospedale San Raffaele S.r.l. Milan Italy
Uzqccpiysfjcgdwqwoeki Eedoo Ale Essen Germany
Utdgldqkyozhzvwtlqaga Majpstxn Akw Munster Germany

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Germany Germany
Not recruiting
07.02.2023
Italy Italy
Not recruiting
07.02.2023

Trial locations

Investigated drugs:

Reparixin is being studied as an additional treatment to the usual care for adults with Acute Respiratory Distress Syndrome (ARDS). The trial aims to see if reparixin can help reduce lung damage and inflammation, speed up recovery, and help patients come off mechanical ventilation sooner. The study also looks at how reparixin affects certain markers in the body that are linked to a more severe form of ARDS.

Investigated diseases:

Acute Respiratory Distress Syndrome – Acute Respiratory Distress Syndrome (ARDS) is a severe lung condition that occurs when fluid builds up in the tiny, elastic air sacs (alveoli) in the lungs. This fluid prevents the lungs from filling with enough air, which means less oxygen reaches the bloodstream. ARDS typically develops in people who are already critically ill or who have significant injuries. The condition progresses rapidly, often within a few hours to a few days after the initial injury or illness. It leads to severe shortness of breath and requires medical intervention, often involving mechanical ventilation. The progression of ARDS can vary, but it generally involves worsening respiratory function and increased difficulty in breathing.

Trial ID:
2024-512621-88-00
Protocol code:
REP0122
NCT ID:
NCT05496868
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study on Anticoagulation Strategies with Heparin, Enoxaparin, and Argatroban for Patients with Respiratory or Circulatory Failure on ECMO Support

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

  • Study of High-Dose Vitamin C (Ascorbic Acid) Compared to Placebo in Patients with Sepsis and Acute Respiratory Distress Syndrome (ARDS) in Intensive Care

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France